GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Beginning Cash Position

Zai Lab (HKSE:09688) Beginning Cash Position : HK$6,190 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Beginning Cash Position?

Zai Lab's Beginning Cash Position for the quarter that ended in Mar. 2024 was HK$6,190 Mil.

Zai Lab's quarterly Beginning Cash Position declined from Sep. 2023 (HK$6,740 Mil) to Dec. 2023 (HK$6,174 Mil) but then increased from Dec. 2023 (HK$6,174 Mil) to Mar. 2024 (HK$6,190 Mil).

Zai Lab's annual Beginning Cash Position increased from Dec. 2021 (HK$3,454 Mil) to Dec. 2022 (HK$7,512 Mil) and increased from Dec. 2022 (HK$7,512 Mil) to Dec. 2023 (HK$7,882 Mil).


Zai Lab Beginning Cash Position Historical Data

The historical data trend for Zai Lab's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Beginning Cash Position Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 491.31 592.57 3,453.86 7,512.16 7,882.22

Zai Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,921.48 6,899.68 6,739.92 6,174.41 6,190.06

Zai Lab Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Zai Lab Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Zai Lab's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (HKSE:09688) Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Wellington Management Group Llp 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Janus Henderson Group Plc 2102 Investment manager
Du Ying 2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab (HKSE:09688) Headlines

No Headlines